Lacosamide Injection
Product Images NDC 70710-1886

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 70710-1886). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (32f7b181 F883 4d8f 8557 2c5a4eac51ee 01)

Chemical structure diagram of the active ingredient Lacosamide, showing its molecular connectivity and functional groups.*

FDA Label Image

Image (32f7b181 F883 4d8f 8557 2c5a4eac51ee 02)

A bar graph showing seizure reduction (median % change from baseline) across three studies (Study 2, Study 3, Study 4) comparing placebo and lacosamide at various dosages. The y-axis represents seizure reduction percentage, while the x-axis categorizes treatment groups by placebo and lacosamide dosages. Each study shows greater seizure reduction with lacosamide versus placebo, with statistically significant differences marked.*

FDA Label Image

Image (32f7b181 F883 4d8f 8557 2c5a4eac51ee 03)

A line graph depicting responder rate (equal to or greater improvement) on the vertical axis versus percent of patients on the horizontal axis. The graph compares four groups: placebo and lacosamide at doses of 200 mg/day, 400 mg/day, and 600 mg/day, each with different sample sizes. Each group is represented by a distinct line pattern showing trends in patient response rates.*

FDA Label Image

Image (32f7b181 F883 4d8f 8557 2c5a4eac51ee 04)

A Kaplan-Meier survival curve comparing the proportion of patients over time between Lacosamide (N=118) and placebo (N=121) groups. The y-axis shows the proportion of patients, and the x-axis shows time in days. The graph includes a p-value of 0.001, hazard ratio (HR) of 0.548 indicating risk reduction, and 95% confidence interval (CI). Number at risk is presented below the x-axis for both study groups at different time points.*

FDA Label Image

Lacosamide Injection (32f7b181 F883 4d8f 8557 2c5a4eac51ee 05)

Label for Lacosamide Injection, USP 10 mg/mL intravenous injection, 20 mL single-dose vial. The label shows strength as 200 mg/20 mL and includes usage instructions, storage conditions, and manufacturer information. Distributed by Zydus Pharmaceuticals (USA) Inc. Contains a barcode and a mention that the container closure is latex-free.*

FDA Label Image

Lacosamide Injection (32f7b181 F883 4d8f 8557 2c5a4eac51ee 06)

Lacosamide Injection, USP 200 mg/20 mL (10 mg/mL) intravenous injection in a carton. The label states it is for intravenous use only, Rx only, packaged as 10 single-dose 20 mL vials. Manufactured by Zydus Lifesciences Ltd. and distributed by Zydus Pharmaceuticals USA Inc. The label includes dosing and storage information and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.